[go: up one dir, main page]

ES2196303T3 - Administracion de nicotina por el colon para tratar enfermedades intestinales inflamatorias. - Google Patents

Administracion de nicotina por el colon para tratar enfermedades intestinales inflamatorias.

Info

Publication number
ES2196303T3
ES2196303T3 ES97904516T ES97904516T ES2196303T3 ES 2196303 T3 ES2196303 T3 ES 2196303T3 ES 97904516 T ES97904516 T ES 97904516T ES 97904516 T ES97904516 T ES 97904516T ES 2196303 T3 ES2196303 T3 ES 2196303T3
Authority
ES
Spain
Prior art keywords
nicotine
colon
administration
treat inflammatory
intestinal diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97904516T
Other languages
English (en)
Other versions
ES2196303T5 (es
Inventor
William Jeffery Sandborn
John Rhodes
Peter Rhodes
Brian Kenneth Evans
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mayo Foundation for Medical Education and Research
Mayo Clinic in Florida
Original Assignee
Mayo Foundation for Medical Education and Research
Mayo Clinic in Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24423169&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2196303(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mayo Foundation for Medical Education and Research, Mayo Clinic in Florida filed Critical Mayo Foundation for Medical Education and Research
Application granted granted Critical
Publication of ES2196303T3 publication Critical patent/ES2196303T3/es
Publication of ES2196303T5 publication Critical patent/ES2196303T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Colloid Chemistry (AREA)

Abstract

SE PROPORCIONA UN PROCEDIMIENTO PARA TRATAR LA ENFERMEDAD INFLAMATORIA DEL INTESTINO POR ADMINISTRACION LOCAL AL COLON DE UNA CANTIDAD EFECTIVA DE NICOTINA, O DE UNA SAL FARMACEUTICAMENTE ACEPTABLE DE LA MISMA, PREFERENTEMENTE A TRAVES DE FORMULACIONES ADAPTADAS PARA LIBERACION ORAL RETARDADA O ADMINISTRACION RECTAL. SE PROPORCIONA, ADEMAS, UNA NUEVA FORMULA PARA LA ADMINISTRACION ORAL DE NICOTINA, QUE COMPRENDE UN COPOLIMERO POLIACRILICO COMPLEXADO CON NICOTINA.
ES97904516T 1996-02-09 1997-02-07 Administracion de nicotina por el colon para tratar enfermedades intestinales inflamatorias. Expired - Lifetime ES2196303T5 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US605319 1990-10-30
US08/605,319 US5846983A (en) 1996-02-09 1996-02-09 Colonic delivery of nicotine to treat inflammatory bowel disease

Publications (2)

Publication Number Publication Date
ES2196303T3 true ES2196303T3 (es) 2003-12-16
ES2196303T5 ES2196303T5 (es) 2008-05-01

Family

ID=24423169

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97904516T Expired - Lifetime ES2196303T5 (es) 1996-02-09 1997-02-07 Administracion de nicotina por el colon para tratar enfermedades intestinales inflamatorias.

Country Status (20)

Country Link
US (1) US5846983A (es)
EP (1) EP0893998B2 (es)
JP (1) JP4283340B2 (es)
KR (1) KR100458636B1 (es)
CN (1) CN1127340C (es)
AT (1) ATE237330T1 (es)
AU (1) AU718971C (es)
CA (1) CA2246235C (es)
CZ (1) CZ293616B6 (es)
DE (1) DE69720985T3 (es)
DK (1) DK0893998T4 (es)
ES (1) ES2196303T5 (es)
HU (1) HUP9900950A3 (es)
MX (1) MX9806354A (es)
MY (1) MY122023A (es)
PL (1) PL187914B1 (es)
PT (1) PT893998E (es)
SK (1) SK284539B6 (es)
WO (1) WO1997028801A1 (es)
ZA (1) ZA971020B (es)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5889028A (en) * 1996-02-09 1999-03-30 Mayo Foundation For Medical Education And Research Colonic delivery of nicotine to treat inflammatory bowel disease
GB9614902D0 (en) 1996-07-16 1996-09-04 Rhodes John Sustained release composition
US6268386B1 (en) * 1998-06-25 2001-07-31 Marshall Anlauf Thompson Nicotine beverage
ES2211184T3 (es) * 1998-08-06 2004-07-01 Wolfgang Stremmel Fosfatidilcolina como medicamento con efecto protector de mucosas.
ATE446767T1 (de) * 1999-02-12 2009-11-15 Univ Washington Gm-csf zur behandlung von morbus crohn
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
EP1225897B1 (en) * 1999-11-01 2004-09-08 RHODES, John Composition for treatment of constipation and irritable bowel syndrome
US8512718B2 (en) 2000-07-03 2013-08-20 Foamix Ltd. Pharmaceutical composition for topical application
IT1318625B1 (it) 2000-07-14 2003-08-27 Roberto Valducci Formulazioni farmaceutiche solide orali a rilascio multifasicoph-dipendente.
ATE485837T1 (de) * 2000-08-03 2010-11-15 Antares Pharma Ipl Ag Zusammensetzung zur transdermalen und/oder transmukosalen verabreichung von wirkstoffen, die ausreichende therapeutische spiegel garantiert
US7198801B2 (en) 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
US8980290B2 (en) 2000-08-03 2015-03-17 Antares Pharma Ipl Ag Transdermal compositions for anticholinergic agents
US20050130990A1 (en) * 2001-03-23 2005-06-16 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory diseases
CA2341952A1 (en) * 2001-03-23 2002-09-23 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory pulmonary diseases
US20030108592A1 (en) * 2001-12-10 2003-06-12 Thompson Marshall Anlauf Method of producing a nicotine composition
US20060204598A1 (en) * 2001-12-10 2006-09-14 Thompson Marshall A Nicotine-alternative compositions and methods of producing such compositions
US20100160376A1 (en) * 2001-12-10 2010-06-24 Marshall Anlauf Thompson Nicotine-alternative compositions and methods of producing such compositions
US20050131031A1 (en) * 2001-12-10 2005-06-16 Thompson Marshall A. Method of producing a nicotine composition
US7091357B2 (en) 2001-12-26 2006-08-15 University Of Kentucky Research Foundation Chain-modified pyridino-N substituted nicotine compounds for use in the treatment of CNS pathologies
US8557804B2 (en) 2002-03-25 2013-10-15 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory diseases
US8039459B2 (en) * 2004-07-15 2011-10-18 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory diseases
IL152486A0 (en) 2002-10-25 2003-05-29 Meir Eini Alcohol-free cosmetic and pharmaceutical foam carrier
US10117812B2 (en) 2002-10-25 2018-11-06 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US7704518B2 (en) 2003-08-04 2010-04-27 Foamix, Ltd. Foamable vehicle and pharmaceutical compositions thereof
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
ES2532906T5 (es) 2002-10-25 2022-03-23 Foamix Pharmaceuticals Ltd Espuma cosmética y farmacéutica
US8900554B2 (en) 2002-10-25 2014-12-02 Foamix Pharmaceuticals Ltd. Foamable composition and uses thereof
US8486376B2 (en) 2002-10-25 2013-07-16 Foamix Ltd. Moisturizing foam containing lanolin
US8119109B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Foamable compositions, kits and methods for hyperhidrosis
US7700076B2 (en) 2002-10-25 2010-04-20 Foamix, Ltd. Penetrating pharmaceutical foam
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US7820145B2 (en) 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US8119150B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Non-flammable insecticide composition and uses thereof
US20080138296A1 (en) 2002-10-25 2008-06-12 Foamix Ltd. Foam prepared from nanoemulsions and uses
US8084432B2 (en) * 2003-02-13 2011-12-27 Isis Pharmaceuticals, Inc. Compositions and methods for treatment of pouchitis
US7575739B2 (en) 2003-04-28 2009-08-18 Foamix Ltd. Foamable iodine composition
US8486374B2 (en) 2003-08-04 2013-07-16 Foamix Ltd. Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses
US8795693B2 (en) 2003-08-04 2014-08-05 Foamix Ltd. Compositions with modulating agents
PL1670433T3 (pl) 2003-10-10 2013-03-29 Ferring Bv Przezskórna formulacja farmaceutyczna do zmniejszania pozostałości na skórze
ES2257152B1 (es) * 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
CA2580329C (en) 2004-09-13 2015-01-06 Chrono Therapeutics Inc. Biosynchronous transdermal drug delivery
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
WO2006080919A1 (en) * 2005-01-27 2006-08-03 Marshall Anlauf Thompson Method of producing a nicotine composition
US8067399B2 (en) 2005-05-27 2011-11-29 Antares Pharma Ipl Ag Method and apparatus for transdermal or transmucosal application of testosterone
CN101426475A (zh) 2006-04-21 2009-05-06 安塔雷斯制药Ipl股份公司 使用用于经皮或经粘膜应用的制剂治疗热潮红的方法
US20080260655A1 (en) 2006-11-14 2008-10-23 Dov Tamarkin Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
US20100143270A1 (en) * 2007-02-21 2010-06-10 University Of Louisville Research Foubdation Therapeutic cotinine compositions
GB2468424B (en) * 2007-04-02 2011-11-09 Parkinson S Inst Methods and compositions for reduction of side effects of therapeutic treatments
US8636982B2 (en) 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
WO2009069006A2 (en) 2007-11-30 2009-06-04 Foamix Ltd. Foam containing benzoyl peroxide
US8518376B2 (en) 2007-12-07 2013-08-27 Foamix Ltd. Oil-based foamable carriers and formulations
WO2009090495A2 (en) 2007-12-07 2009-07-23 Foamix Ltd. Oil and liquid silicone foamable carriers and formulations
CA2712120A1 (en) 2008-01-14 2009-07-23 Foamix Ltd. Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses
EP2100598A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
US20120087872A1 (en) 2009-04-28 2012-04-12 Foamix Ltd. Foamable Vehicles and Pharmaceutical Compositions Comprising Aprotic Polar Solvents and Uses Thereof
WO2011013008A2 (en) 2009-07-29 2011-02-03 Foamix Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
CA2769625C (en) 2009-07-29 2017-04-11 Foamix Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
WO2011039637A2 (en) 2009-10-02 2011-04-07 Foamix Ltd. Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
US20130017259A1 (en) 2011-07-06 2013-01-17 The Parkinson's Institute Compositions and Methods for Treatment of Symptoms in Parkinson's Disease Patients
CA2876540C (en) * 2012-06-15 2022-11-29 Conaris Research Institute Ag A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota
JP6895752B2 (ja) 2013-12-13 2021-06-30 コナリス リサーチ インスティチュート アーゲー ニコチン酸および／またはニコチンアミドを含む、腸内微生物叢を改変することにより血中脂質レベルに有益に影響を及ぼすための医薬組成物
WO2015086838A2 (en) 2013-12-13 2015-06-18 Conaris Research Institute Ag A pharmaceutical composition containing combinations of nicotinamide and 5-aminosalicylic acid for beneficially influencing the intestinal microbiota and/or treating gastrointestinal inflammation
GB201400442D0 (en) * 2014-01-10 2014-02-26 Sigmoid Pharma Ltd Compositions for use in the treatment of ulcerative colitis
CA2974324A1 (en) 2015-01-28 2016-08-04 Zita S. Netzel Drug delivery methods and systems
WO2016145373A1 (en) 2015-03-12 2016-09-15 Chrono Therapeutics Inc. Craving input and support system
US10398641B2 (en) 2016-09-08 2019-09-03 Foamix Pharmaceuticals Ltd. Compositions and methods for treating rosacea and acne
EP3565617A1 (en) 2017-01-06 2019-11-13 Chrono Therapeutics Inc. Transdermal drug delivery devices and methods
US11596779B2 (en) 2018-05-29 2023-03-07 Morningside Venture Investments Limited Drug delivery methods and systems
CA3119992A1 (en) 2018-11-16 2020-05-22 Morningside Venture Investments Limited Thermally regulated transdermal drug delivery system
WO2021030474A1 (en) 2019-08-12 2021-02-18 Massachusetts Institute Of Technology Articles and methods for administration of therapeutic agents
CN115089641B (zh) * 2022-05-25 2023-07-25 西安交通大学医学院第一附属医院 一种难治型溃疡性结肠炎灌肠剂及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3645036A1 (de) * 1986-11-18 1989-01-05 Forschungsgesellschaft Rauchen Nikotinhaltiges mittel
US4855142A (en) * 1987-02-27 1989-08-08 Ciba-Geigy Corporation Pharmaceutical plaster
IE62662B1 (en) * 1989-01-06 1995-02-22 Elan Corp Plc Use of nicotine in the treatment of conditions susceptible to said treatment
KR100193933B1 (ko) * 1990-07-20 1999-06-15 에밀리오 캠포레시, 존 페르구손 비스무트와 폴리아크릴레이트와의 수용성 착체, 이의 제조 방법 및 상기 착체 또는 다른 비스무트염을 함유하는 궤양성 대장염 치료용 약제학적 조성물
GEP19971086B (en) * 1991-02-22 1997-12-02 Tillotts Pharma Ag Peroral Pharmaceutically Dispensed Form for Selective Introducing of the Medicine into the Intestine
GB9310412D0 (en) * 1993-05-20 1993-07-07 Danbiosyst Uk Nasal nicotine system
KR0121127B1 (ko) * 1994-05-09 1997-11-13 강박광 이온성 고분자 네트웍을 갖는 피부약물전달체계
US5604231A (en) * 1995-01-06 1997-02-18 Smith; Carr J. Pharmaceutical compositions for prevention and treatment of ulcerative colitis
US5532254A (en) † 1995-06-07 1996-07-02 Eli Lilly And Company Modulation of calcium channels using benzothiophenes
GB9614902D0 (en) * 1996-07-16 1996-09-04 Rhodes John Sustained release composition

Also Published As

Publication number Publication date
ATE237330T1 (de) 2003-05-15
PL187914B1 (pl) 2004-10-29
EP0893998A1 (en) 1999-02-03
MX9806354A (es) 1998-10-31
AU1729497A (en) 1997-08-28
DE69720985T3 (de) 2008-05-29
AU718971B2 (en) 2000-05-04
EP0893998B2 (en) 2007-12-12
CN1210466A (zh) 1999-03-10
DE69720985D1 (de) 2003-05-22
MY122023A (en) 2006-03-31
KR100458636B1 (ko) 2005-01-15
HUP9900950A3 (en) 2000-01-28
ES2196303T5 (es) 2008-05-01
US5846983A (en) 1998-12-08
PT893998E (pt) 2003-07-31
CZ245198A3 (cs) 1999-05-12
KR19990082429A (ko) 1999-11-25
DK0893998T3 (da) 2003-08-11
EP0893998B1 (en) 2003-04-16
PL328430A1 (en) 1999-02-01
HK1019043A1 (en) 2000-01-21
WO1997028801A1 (en) 1997-08-14
HUP9900950A2 (hu) 1999-08-30
CA2246235A1 (en) 1997-08-14
DE69720985T2 (de) 2004-02-05
CZ293616B6 (cs) 2004-06-16
SK106898A3 (en) 2000-12-11
DK0893998T4 (da) 2008-05-05
CN1127340C (zh) 2003-11-12
JP4283340B2 (ja) 2009-06-24
JP2000505430A (ja) 2000-05-09
ZA971020B (en) 1997-11-05
SK284539B6 (sk) 2005-06-02
CA2246235C (en) 2007-06-12
AU718971C (en) 2008-01-31

Similar Documents

Publication Publication Date Title
ES2196303T3 (es) Administracion de nicotina por el colon para tratar enfermedades intestinales inflamatorias.
BR0115910A (pt) Compostos orgânicos
DE60335639D1 (de) Prävention und/oder behandlung von colitis ulcerosa mit pyy oder pyyä3-36ü
CY1106763T1 (el) Προληπτικα ή θεραπευτικα μεσα για φλεγμονωδεις νοσους του εντερου
MY138352A (en) Benzothiazole derivatives
ES2053571T3 (es) Uso de propionato de fluticasona en la preparacion de una composicion farmaceutica para el tratamiento de enfermedades intestinales.
PA8452001A1 (es) Derivados de macrolidos c-4" sustituidos
MX9203444A (es) Medicamentos.
NO2012015I1 (no) Dapoxetine i en hver form beskyttet av basis patent nr 330562
DK0998287T3 (da) Anvendelse af levobupivacain
GT199900015A (es) Procedimiento para tratar la insuficiencia cardiaca
CY1114422T1 (el) Φαρμακευτικη συνθεση που περιλαμβανει αρσενικωδες για τη θεραπευτικη αντιμετωπιση κακοηθειας
SE9700934D0 (sv) New formulation
CO5190674A1 (es) Tratamiento de desordenes neuroticos desordenes neuroticos
IT1318667B1 (it) Medicamento antinfiammatorio.
ES2052533T3 (es) Composicion farmaceutica que comprende 2',3'-didesoxicitidin-2'-eno (2',3'-dideshidrocitidina) para tratar pacientes infectados con retrovirus.
ES2090875T3 (es) Tratamiento de enfermedades inflamatorias del intestino.
DE69924146D1 (de) Etherlysophospholipide zur behandlung von chronischen entzündlichen erkrankungen
IT8219482A0 (it) Composizione farmaceutica per la cura di affezioni della cavita'orale.
RU94014833A (ru) Средство для лечения дегенеративных заболеваний суставов и околосуставных тканей
AR022348A1 (es) Una composicion farmaceutica para el tratamiento de los sintomas del tracto urinario inferior
ES2111013T3 (es) Una composicion profilactica/terapeutica que contiene ws7622a para evitar o tratar la coagulacion intravascular diseminada, la enfermedad infecciosa cronica del tracto respiratorio o la bronquitis cronica.
ATE248607T1 (de) Aminotetralin derivate zur therapie der kardiovaskulären erkrankungen
ATE74505T1 (de) Schmerzpraeparat.
UY26405A1 (es) Método para tratar el mal de parkinson a través de la administración de (-)-5-ceto-2-n,n-d1-n-propilamino-tetrahidrotetralina.